Tag Archive for: Novo Holdings

Novo Holdings co-leads £90 million ($114 million) Series A financing for Myricx Bio to advance a novel payload class for antibody-drug conjugates

Funds will be used to build out Myricx Bio’s proprietary payload platform and advance its pipeline through clinical proof of concept Novo Holdings Venture Investments Partner Michael Bauer will join Myricx Board of Directors and Principal Max Klement will join Myricx Board as an Observer This is the largest European biotech Series A financing this […]

Novo Holdings invests in MATR Foods’ expansion within plant-based fungi food

COPENHAGEN, DENMARK – Today, Novo Holdings announced an initial investment in Danish food-tech start-up MATR Foods (‘MATR’) to support the scaling-up of its production of sustainable meat alternatives. Established in Copenhagen in 2021, MATR specialises in developing organic innovative plant-based meat alternatives using traditional fungal fermentation techniques. Locally sourced organic ingredients like oats, split peas, […]

Novo Holdings and DLG Group join forces to advance sustainable crop production

Novo Holdings and DLG Group today announced a strategic partnership to advance sustainable agriculture and food systems. The initial phase includes Novo Holdings acquiring 25% of the shares in Sejet Plant Breeding (Sejet), a leader in agricultural innovation owned by DLG Group. Since 1947, Sejet has been a leading contributor to agricultural innovation, developing and delivering […]

Novo Holdings announces investment in AgNext Technologies, an agricultural and food technology company developing AI-based solutions for more sustainable agriculture

Copenhagen and Singapore, 25 June 2024 – Novo Holdings today announced that it has led an investment in AgNext Technologies Private Limited, a breakthrough agricultural and food technology company enhancing trust along the food chains by innovating artificial intelligence-based food quality assessment technologies. Founded in 2016 with operations in India and Abu Dhabi, UAE, AgNext Technologies […]

Novo Holdings portfolio company Numab Therapeutics announces Johnson & Johnson (‘J&J’) to acquire its wholly-owned subsidiary Yellow Jersey Therapeutics

Under the agreement terms, J&J will pay $1.25 billion to acquire Yellow Jersey Therapeutics, which holds NM26 rights, and will gain full rights to develop, manufacture and commercialize NM26 globally for the treatment of atopic dermatitis and follow-on indications NM26 is a Phase 2-ready bi-specific antibody from Numab’s pipeline of candidates discovered and engineered using […]